Fig. 2

Insig2 deficiency exacerbates hepatic IR injury. A Diagram of the Insig2-KO strategy. B sALT and sAST levels in WT and Insig2-KO mice in the sham group (n = 3/group) and at 6 h after hepatic IR (n = 6/group). C Representative HE staining and statistics showing necrotic areas of liver tissue from WT and Insig2-KO mice at 6 h after hepatic IR (n = 3/group). D Western blot analysis of Bax and Bcl2 expression in livers from WT and Insig2-KO mice at 6 h after IR (n = 4/group). E TUNEL staining and statistics in ischemic liver sections from mice in the indicated groups (n = 3/group). IHC staining of cleaved-caspase-3 expression and statistics in ischemic liver sections from mice in the indicated groups (n = 3/group). F The serum levels of inflammatory cytokines (IL-6, IL-1β, TNF-α) in WT and Insig2-KO mice at 6 h after hepatic IR (n = 5/group). G Real-time quantitative PCR (RT-PCR) analysis of the mRNA levels of IL-6, IL-1β, TNF-α, Ccl2 and Cxcl10 in WT and Insig2-KO mice at 6 h after hepatic IR (n = 4/group). H Representative MPO and F4/80 immunofluorescent staining (red) in liver sections of WT and Insig2-KO mice at sham or IR surgery (n = 3/group). All data are shown as means ± SDs. ns indicates no significance between the two indicated groups; *p < 0.05; **p < 0.01